APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antiviral Traditional Chinese Medicine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Antiviral Traditional Chinese Medicine Market Outlook and Growth Opportunities 2026

2 January 2026216 pages

Choose your research edition.

Industry ResearchAntiviral Traditional Chinese Medicine Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal Antiviral Traditional Chinese Medicine Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Antiviral Traditional Chinese Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antiviral Traditional Chinese Medicine Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal Antiviral Traditional Chinese Medicine Market Analysis and Forecast 2026-2032214 pages · $4,950 USD

Market perspective

The global Antiviral Traditional Chinese Medicine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Antiviral Traditional Chinese Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antiviral Traditional Chinese Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antiviral Traditional Chinese Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Antiviral Traditional Chinese Medicine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Antiviral Traditional Chinese Medicine market include Buchang Pharmaceutical, Guangzhou Pharmaceutical, Harbin Pharmaceutical Group, Harbin Pharmaceutical Group, Shineway Pharmaceutical, Fusen Pharmaceutical, Gerun Pharmaceutical, CR SANJIU and Jumpcan, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Antiviral Traditional Chinese Medicine market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antiviral Traditional Chinese Medicine and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antiviral Traditional Chinese Medicine revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Antiviral Traditional Chinese Medicine market.

Antiviral Traditional Chinese Medicine Segment by Company

Buchang Pharmaceutical

Guangzhou Pharmaceutical

Harbin Pharmaceutical Group

Harbin Pharmaceutical Group

Shineway Pharmaceutical

Fusen Pharmaceutical

Gerun Pharmaceutical

CR SANJIU

Jumpcan

Qingfeng Pharmaceutical Group

Livzon

Green Valley Pharma

Chase Sun Pharmaceutical

TASLY

Yusheng Pharmaceutical

Tongrentang

Wuzhou Pharmaceutical

Yiling Pharmaceutical

Yunnan Baiyao

Changbaishan Pharmaceutical

Zhejiang Conba Pharmaceutical

Zhejiang Kanglaite Pharmaceutical

ZBD Pharmaceutical

China TCM

Antiviral Traditional Chinese Medicine Segment by Type

Anti-herpes Virus

Anti-influenza Virus

Anti-HIV

Anti-HBV

Anti-CVB

Other

Antiviral Traditional Chinese Medicine Segment by Application

Adult

Children

Antiviral Traditional Chinese Medicine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Antiviral Traditional Chinese Medicine status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Antiviral Traditional Chinese Medicine key companies, revenue, market share, and recent developments.

3. To split the Antiviral Traditional Chinese Medicine breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Antiviral Traditional Chinese Medicine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antiviral Traditional Chinese Medicine significant trends, drivers, influence factors in global and regions.

6. To analyze Antiviral Traditional Chinese Medicine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antiviral Traditional Chinese Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antiviral Traditional Chinese Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antiviral Traditional Chinese Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antiviral Traditional Chinese Medicine industry.

Chapter 3: Detailed analysis of Antiviral Traditional Chinese Medicine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Antiviral Traditional Chinese Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Antiviral Traditional Chinese Medicine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antiviral Traditional Chinese Medicine Industry Trends Table 2. Antiviral Traditional Chinese Medicine Industry Drivers Table 3. Antiviral Traditional Chinese Medicine Industry Opportunities and Challenges Table 4. Antiviral Traditional Chinese Medicine Industry Restraints Table 5. Global Antiviral Traditional Chinese Medicine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antiviral Traditional Chinese Medicine Revenue Share by Company (2021-2026) Table 7. Global Antiviral Traditional Chinese Medicine Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Antiviral Traditional Chinese Medicine Key Company Manufacturing Base & Headquarters Table 9. Global Antiviral Traditional Chinese Medicine Company, Product Type & Application Table 10. Global Antiviral Traditional Chinese Medicine Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Antiviral Traditional Chinese Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Anti-herpes Virus Table 15. Significant Companies of Anti-influenza Virus Table 16. Significant Companies of Anti-HIV Table 17. Significant Companies of Anti-HBV Table 18. Significant Companies of Anti-CVB Table 19. Significant Companies of Other Table 20. Global Antiviral Traditional Chinese Medicine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global Antiviral Traditional Chinese Medicine Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global Antiviral Traditional Chinese Medicine Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global Antiviral Traditional Chinese Medicine Sales Value Share by Type (2021-2026) Table 24. Global Antiviral Traditional Chinese Medicine Sales Value Share by Type (2027-2032) Table 25. Significant Companies of Adult Table 26. Significant Companies of Children Table 27. Global Antiviral Traditional Chinese Medicine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Antiviral Traditional Chinese Medicine Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Antiviral Traditional Chinese Medicine Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Antiviral Traditional Chinese Medicine Sales Value Share by Application (2021-2026) Table 31. Global Antiviral Traditional Chinese Medicine Sales Value Share by Application (2027-2032) Table 32. Global Antiviral Traditional Chinese Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Antiviral Traditional Chinese Medicine Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Antiviral Traditional Chinese Medicine Sales Value Share by Region (2021-2026) Table 35. Global Antiviral Traditional Chinese Medicine Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Antiviral Traditional Chinese Medicine Sales Value Share by Region (2027-2032) Table 37. Global Antiviral Traditional Chinese Medicine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Antiviral Traditional Chinese Medicine Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Antiviral Traditional Chinese Medicine Sales Value Market Share by Country (2021-2026) Table 40. Global Antiviral Traditional Chinese Medicine Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Antiviral Traditional Chinese Medicine Sales Value Market Share by Country (2027-2032) Table 42. Buchang Pharmaceutical Company Information Table 43. Buchang Pharmaceutical Business Overview Table 44. Buchang Pharmaceutical Antiviral Traditional Chinese Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Buchang Pharmaceutical Antiviral Traditional Chinese Medicine Product Portfolio Table 46. Buchang Pharmaceutical Recent Development Table 47. Guangzhou Pharmaceutical Company Information Table 48. Guangzhou Pharmaceutical Business Overview Table 49. Guangzhou Pharmaceutical Antiviral Traditional Chinese Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Guangzhou Pharmaceutical Antiviral Traditional Chinese Medicine Product Portfolio Table 51. Guangzhou Pharmaceutical Recent Development Table 52. Harbin Pharmaceutical Group Company Information Table 53. Harbin Pharmaceutical Group Business Overview Table 54. Harbin Pharmaceutical Group Antiviral Traditional Chinese Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Harbin Pharmaceutical Group Antiviral Traditional Chinese Medicine Product Portfolio Table 56. Harbin Pharmaceutical Group Recent Development Table 57. Harbin Pharmaceutical Group Company Information Table 58. Harbin Pharmaceutical Group Business Overview Table 59. Harbin Pharmaceutical Group Antiviral Traditional Chinese Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Harbin Pharmaceutical Group Antiviral Traditional Chinese Medicine Product Portfolio Table 61. Harbin Pharmaceutical Group Recent Development Table 62. Shineway Pharmaceutical Company Information Table 63. Shineway Pharmaceutical Business Overview Table 64. Shineway Pharmaceutical Antiviral Traditional Chinese Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Shineway Pharmaceutical Antiviral Traditional Chinese Medicine Product Portfolio Table 66. Shineway Pharmaceutical Recent Development Table 67. Fusen Pharmaceutical Company Information Table 68. Fusen Pharmaceutical Business Overview Table 69. Fusen Pharmaceutical Antiviral Traditional Chinese Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Fusen Pharmaceutical Antiviral Traditional Chinese Medicine Product Portfolio Table 71. Fusen Pharmaceutical Recent Development Table 72. Gerun Pharmaceutical Company Information Table 73. Gerun Pharmaceutical Business Overview Table 74. Gerun Pharmaceutical Antiviral Traditional Chinese Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Gerun Pharmaceutical Antiviral Traditional Chinese Medicine Product Portfolio Table 76. Gerun Pharmaceutical Recent Development Table 77. CR SANJIU Company Information Table 78. CR SANJIU Business Overview Table 79. CR SANJIU Antiviral Traditional Chinese Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. CR SANJIU Antiviral Traditional Chinese Medicine Product Portfolio Table 81. CR SANJIU Recent Development Table 82. Jumpcan Company Information Table 83. Jumpcan Business Overview Table 84. Jumpcan Antiviral Traditional Chinese Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Jumpcan Antiviral Traditional Chinese Medicine Product Portfolio Table 86. Jumpcan Recent Development Table 87. Qingfeng Pharmaceutical Group Company Information Table 88. Qingfeng Pharmaceutical Group Business Overview Table 89. Qingfeng Pharmaceutical Group Antiviral Traditional Chinese Medicine Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Qingfeng Pharmaceutical Group Antiviral Traditional Chinese Medicine Product Portfolio Table 91. Qingfeng Pharmaceutical Group Recent Development Table 92. Livzon Company Information Table 93. Livzon Business Overview Table 94. Livzon Antiviral Traditional Chinese Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Livzon Antiviral Traditional Chinese Medicine Product Portfolio Table 96. Livzon Recent Development Table 97. Green Valley Pharma Company Information Table 98. Green Valley Pharma Business Overview Table 99. Green Valley Pharma Antiviral Traditional Chinese Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Green Valley Pharma Antiviral Traditional Chinese Medicine Product Portfolio Table 101. Green Valley Pharma Recent Development Table 102. Chase Sun Pharmaceutical Company Information Table 103. Chase Sun Pharmaceutical Business Overview Table 104. Chase Sun Pharmaceutical Antiviral Traditional Chinese Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Chase Sun Pharmaceutical Antiviral Traditional Chinese Medicine Product Portfolio Table 106. Chase Sun Pharmaceutical Recent Development Table 107. TASLY Company Information Table 108. TASLY Business Overview Table 109. TASLY Antiviral Traditional Chinese Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. TASLY Antiviral Traditional Chinese Medicine Product Portfolio Table 111. TASLY Recent Development Table 112. Yusheng Pharmaceutical Company Information Table 113. Yusheng Pharmaceutical Business Overview Table 114. Yusheng Pharmaceutical Antiviral Traditional Chinese Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Yusheng Pharmaceutical Antiviral Traditional Chinese Medicine Product Portfolio Table 116. Yusheng Pharmaceutical Recent Development Table 117. Tongrentang Company Information Table 118. Tongrentang Business Overview Table 119. Tongrentang Antiviral Traditional Chinese Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Tongrentang Antiviral Traditional Chinese Medicine Product Portfolio Table 121. Tongrentang Recent Development Table 122. Wuzhou Pharmaceutical Company Information Table 123. Wuzhou Pharmaceutical Business Overview Table 124. Wuzhou Pharmaceutical Antiviral Traditional Chinese Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Wuzhou Pharmaceutical Antiviral Traditional Chinese Medicine Product Portfolio Table 126. Wuzhou Pharmaceutical Recent Development Table 127. Yiling Pharmaceutical Company Information Table 128. Yiling Pharmaceutical Business Overview Table 129. Yiling Pharmaceutical Antiviral Traditional Chinese Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Yiling Pharmaceutical Antiviral Traditional Chinese Medicine Product Portfolio Table 131. Yiling Pharmaceutical Recent Development Table 132. Yunnan Baiyao Company Information Table 133. Yunnan Baiyao Business Overview Table 134. Yunnan Baiyao Antiviral Traditional Chinese Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Yunnan Baiyao Antiviral Traditional Chinese Medicine Product Portfolio Table 136. Yunnan Baiyao Recent Development Table 137. Changbaishan Pharmaceutical Company Information Table 138. Changbaishan Pharmaceutical Business Overview Table 139. Changbaishan Pharmaceutical Antiviral Traditional Chinese Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Changbaishan Pharmaceutical Antiviral Traditional Chinese Medicine Product Portfolio Table 141. Changbaishan Pharmaceutical Recent Development Table 142. Zhejiang Conba Pharmaceutical Company Information Table 143. Zhejiang Conba Pharmaceutical Business Overview Table 144. Zhejiang Conba Pharmaceutical Antiviral Traditional Chinese Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Zhejiang Conba Pharmaceutical Antiviral Traditional Chinese Medicine Product Portfolio Table 146. Zhejiang Conba Pharmaceutical Recent Development Table 147. Zhejiang Kanglaite Pharmaceutical Company Information Table 148. Zhejiang Kanglaite Pharmaceutical Business Overview Table 149. Zhejiang Kanglaite Pharmaceutical Antiviral Traditional Chinese Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Zhejiang Kanglaite Pharmaceutical Antiviral Traditional Chinese Medicine Product Portfolio Table 151. Zhejiang Kanglaite Pharmaceutical Recent Development Table 152. ZBD Pharmaceutical Company Information Table 153. ZBD Pharmaceutical Business Overview Table 154. ZBD Pharmaceutical Antiviral Traditional Chinese Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. ZBD Pharmaceutical Antiviral Traditional Chinese Medicine Product Portfolio Table 156. ZBD Pharmaceutical Recent Development Table 157. China TCM Company Information Table 158. China TCM Business Overview Table 159. China TCM Antiviral Traditional Chinese Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 160. China TCM Antiviral Traditional Chinese Medicine Product Portfolio Table 161. China TCM Recent Development Table 162. Research Programs/Design for This Report Table 163. Authors List of This Report Table 164. Secondary Sources Table 165. Primary Sources List of Figures Figure 1. Antiviral Traditional Chinese Medicine Product Image Figure 2. Global Antiviral Traditional Chinese Medicine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antiviral Traditional Chinese Medicine Market Size (2021-2032) & (US$ Million) Figure 4. Global Antiviral Traditional Chinese Medicine Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Anti-herpes Virus Image Figure 8. Anti-influenza Virus Image Figure 9. Anti-HIV Image Figure 10. Anti-HBV Image Figure 11. Anti-CVB Image Figure 12. Other Image Figure 13. Global Antiviral Traditional Chinese Medicine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global Antiviral Traditional Chinese Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global Antiviral Traditional Chinese Medicine Sales Value Share by Type (2021-2032) Figure 16. Adult Image Figure 17. Children Image Figure 18. Global Antiviral Traditional Chinese Medicine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Antiviral Traditional Chinese Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Antiviral Traditional Chinese Medicine Sales Value Share by Application (2021-2032) Figure 21. Global Antiviral Traditional Chinese Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Antiviral Traditional Chinese Medicine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Antiviral Traditional Chinese Medicine Sales Value (2021-2032) & (US$ Million) Figure 24. North America Antiviral Traditional Chinese Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Antiviral Traditional Chinese Medicine Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Antiviral Traditional Chinese Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Antiviral Traditional Chinese Medicine Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Antiviral Traditional Chinese Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Antiviral Traditional Chinese Medicine Sales Value (2021-2032) & (US$ Million) Figure 30. South America Antiviral Traditional Chinese Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Antiviral Traditional Chinese Medicine Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Antiviral Traditional Chinese Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Anti-herpes Virus
  • Anti-influenza Virus
  • Anti-HIV
  • Anti-HBV
  • Anti-CVB
  • Other
Applications
  • Adult
  • Children
Companies covered
  • Buchang Pharmaceutical
  • Guangzhou Pharmaceutical
  • Harbin Pharmaceutical Group
  • Harbin Pharmaceutical Group
  • Shineway Pharmaceutical
  • Fusen Pharmaceutical
  • Gerun Pharmaceutical
  • CR SANJIU
  • Jumpcan
  • Qingfeng Pharmaceutical Group
  • Livzon
  • Green Valley Pharma
  • Chase Sun Pharmaceutical
  • TASLY
  • Yusheng Pharmaceutical
  • Tongrentang
  • Wuzhou Pharmaceutical
  • Yiling Pharmaceutical
  • Yunnan Baiyao
  • Changbaishan Pharmaceutical
  • Zhejiang Conba Pharmaceutical
  • Zhejiang Kanglaite Pharmaceutical
  • ZBD Pharmaceutical
  • China TCM

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antiviral Traditional Chinese Medicine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antiviral Traditional Chinese Medicine Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Antiviral Traditional Chinese Medicine Market Dynamics
  1. 2.1 Antiviral Traditional Chinese Medicine Industry Trends
  2. 2.2 Antiviral Traditional Chinese Medicine Industry Drivers
  3. 2.3 Antiviral Traditional Chinese Medicine Industry Opportunities and Challenges
  4. 2.4 Antiviral Traditional Chinese Medicine Industry Restraints
3 Antiviral Traditional Chinese Medicine Market by Company
  1. 3.1 Global Antiviral Traditional Chinese Medicine Company Revenue Ranking in 2025
  2. 3.2 Global Antiviral Traditional Chinese Medicine Revenue by Company (2021-2026)
  3. 3.3 Global Antiviral Traditional Chinese Medicine Company Ranking (2024-2026)
  4. 3.4 Global Antiviral Traditional Chinese Medicine Company Manufacturing Base and Headquarters
  5. 3.5 Global Antiviral Traditional Chinese Medicine Company Product Type and Application
  6. 3.6 Global Antiviral Traditional Chinese Medicine Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Antiviral Traditional Chinese Medicine Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Antiviral Traditional Chinese Medicine Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Antiviral Traditional Chinese Medicine Market by Type
  1. 4.1 Antiviral Traditional Chinese Medicine Type Introduction
  2. 4.1.1 Anti-herpes Virus
  3. 4.1.2 Anti-influenza Virus
  4. 4.1.3 Anti-HIV
  5. 4.1.4 Anti-HBV
  6. 4.1.5 Anti-CVB
  7. 4.1.6 Other
  8. 4.2 Global Antiviral Traditional Chinese Medicine Sales Value by Type
  9. 4.2.1 Global Antiviral Traditional Chinese Medicine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Antiviral Traditional Chinese Medicine Sales Value by Type (2021-2032)
  11. 4.2.3 Global Antiviral Traditional Chinese Medicine Sales Value Share by Type (2021-2032)
5 Antiviral Traditional Chinese Medicine Market by Application
  1. 5.1 Antiviral Traditional Chinese Medicine Application Introduction
  2. 5.1.1 Adult
  3. 5.1.2 Children
  4. 5.2 Global Antiviral Traditional Chinese Medicine Sales Value by Application
  5. 5.2.1 Global Antiviral Traditional Chinese Medicine Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Antiviral Traditional Chinese Medicine Sales Value by Application (2021-2032)
  7. 5.2.3 Global Antiviral Traditional Chinese Medicine Sales Value Share by Application (2021-2032)
6 Antiviral Traditional Chinese Medicine Regional Value Analysis
  1. 6.1 Global Antiviral Traditional Chinese Medicine Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antiviral Traditional Chinese Medicine Sales Value by Region (2021-2032)
  3. 6.2.1 Global Antiviral Traditional Chinese Medicine Sales Value by Region: 2021-2026
  4. 6.2.2 Global Antiviral Traditional Chinese Medicine Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antiviral Traditional Chinese Medicine Sales Value (2021-2032)
  7. 6.3.2 North America Antiviral Traditional Chinese Medicine Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Antiviral Traditional Chinese Medicine Sales Value (2021-2032)
  10. 6.4.2 Europe Antiviral Traditional Chinese Medicine Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Antiviral Traditional Chinese Medicine Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Antiviral Traditional Chinese Medicine Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Antiviral Traditional Chinese Medicine Sales Value (2021-2032)
  16. 6.6.2 South America Antiviral Traditional Chinese Medicine Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Antiviral Traditional Chinese Medicine Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Antiviral Traditional Chinese Medicine Sales Value Share by Country, 2025 VS 2032
7 Antiviral Traditional Chinese Medicine Country-level Value Analysis
  1. 7.1 Global Antiviral Traditional Chinese Medicine Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antiviral Traditional Chinese Medicine Sales Value by Country (2021-2032)
  3. 7.2.1 Global Antiviral Traditional Chinese Medicine Sales Value by Country (2021-2026)
  4. 7.2.2 Global Antiviral Traditional Chinese Medicine Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Antiviral Traditional Chinese Medicine Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Antiviral Traditional Chinese Medicine Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Antiviral Traditional Chinese Medicine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Buchang Pharmaceutical
  2. 8.1.1 Buchang Pharmaceutical Company Information
  3. 8.1.2 Buchang Pharmaceutical Business Overview
  4. 8.1.3 Buchang Pharmaceutical Antiviral Traditional Chinese Medicine Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Buchang Pharmaceutical Antiviral Traditional Chinese Medicine Product Portfolio
  6. 8.1.5 Buchang Pharmaceutical Recent Developments
  7. 8.2 Guangzhou Pharmaceutical
  8. 8.2.1 Guangzhou Pharmaceutical Company Information
  9. 8.2.2 Guangzhou Pharmaceutical Business Overview
  10. 8.2.3 Guangzhou Pharmaceutical Antiviral Traditional Chinese Medicine Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Guangzhou Pharmaceutical Antiviral Traditional Chinese Medicine Product Portfolio
  12. 8.2.5 Guangzhou Pharmaceutical Recent Developments
  13. 8.3 Harbin Pharmaceutical Group
  14. 8.3.1 Harbin Pharmaceutical Group Company Information
  15. 8.3.2 Harbin Pharmaceutical Group Business Overview
  16. 8.3.3 Harbin Pharmaceutical Group Antiviral Traditional Chinese Medicine Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Harbin Pharmaceutical Group Antiviral Traditional Chinese Medicine Product Portfolio
  18. 8.3.5 Harbin Pharmaceutical Group Recent Developments
  19. 8.4 Harbin Pharmaceutical Group
  20. 8.4.1 Harbin Pharmaceutical Group Company Information
  21. 8.4.2 Harbin Pharmaceutical Group Business Overview
  22. 8.4.3 Harbin Pharmaceutical Group Antiviral Traditional Chinese Medicine Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Harbin Pharmaceutical Group Antiviral Traditional Chinese Medicine Product Portfolio
  24. 8.4.5 Harbin Pharmaceutical Group Recent Developments
  25. 8.5 Shineway Pharmaceutical
  26. 8.5.1 Shineway Pharmaceutical Company Information
  27. 8.5.2 Shineway Pharmaceutical Business Overview
  28. 8.5.3 Shineway Pharmaceutical Antiviral Traditional Chinese Medicine Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Shineway Pharmaceutical Antiviral Traditional Chinese Medicine Product Portfolio
  30. 8.5.5 Shineway Pharmaceutical Recent Developments
  31. 8.6 Fusen Pharmaceutical
  32. 8.6.1 Fusen Pharmaceutical Company Information
  33. 8.6.2 Fusen Pharmaceutical Business Overview
  34. 8.6.3 Fusen Pharmaceutical Antiviral Traditional Chinese Medicine Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Fusen Pharmaceutical Antiviral Traditional Chinese Medicine Product Portfolio
  36. 8.6.5 Fusen Pharmaceutical Recent Developments
  37. 8.7 Gerun Pharmaceutical
  38. 8.7.1 Gerun Pharmaceutical Company Information
  39. 8.7.2 Gerun Pharmaceutical Business Overview
  40. 8.7.3 Gerun Pharmaceutical Antiviral Traditional Chinese Medicine Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Gerun Pharmaceutical Antiviral Traditional Chinese Medicine Product Portfolio
  42. 8.7.5 Gerun Pharmaceutical Recent Developments
  43. 8.8 CR SANJIU
  44. 8.8.1 CR SANJIU Company Information
  45. 8.8.2 CR SANJIU Business Overview
  46. 8.8.3 CR SANJIU Antiviral Traditional Chinese Medicine Revenue and Gross Margin (2021-2026)
  47. 8.8.4 CR SANJIU Antiviral Traditional Chinese Medicine Product Portfolio
  48. 8.8.5 CR SANJIU Recent Developments
  49. 8.9 Jumpcan
  50. 8.9.1 Jumpcan Company Information
  51. 8.9.2 Jumpcan Business Overview
  52. 8.9.3 Jumpcan Antiviral Traditional Chinese Medicine Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Jumpcan Antiviral Traditional Chinese Medicine Product Portfolio
  54. 8.9.5 Jumpcan Recent Developments
  55. 8.10 Qingfeng Pharmaceutical Group
  56. 8.10.1 Qingfeng Pharmaceutical Group Company Information
  57. 8.10.2 Qingfeng Pharmaceutical Group Business Overview
  58. 8.10.3 Qingfeng Pharmaceutical Group Antiviral Traditional Chinese Medicine Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Qingfeng Pharmaceutical Group Antiviral Traditional Chinese Medicine Product Portfolio
  60. 8.10.5 Qingfeng Pharmaceutical Group Recent Developments
  61. 8.11 Livzon
  62. 8.11.1 Livzon Company Information
  63. 8.11.2 Livzon Business Overview
  64. 8.11.3 Livzon Antiviral Traditional Chinese Medicine Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Livzon Antiviral Traditional Chinese Medicine Product Portfolio
  66. 8.11.5 Livzon Recent Developments
  67. 8.12 Green Valley Pharma
  68. 8.12.1 Green Valley Pharma Company Information
  69. 8.12.2 Green Valley Pharma Business Overview
  70. 8.12.3 Green Valley Pharma Antiviral Traditional Chinese Medicine Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Green Valley Pharma Antiviral Traditional Chinese Medicine Product Portfolio
  72. 8.12.5 Green Valley Pharma Recent Developments
  73. 8.13 Chase Sun Pharmaceutical
  74. 8.13.1 Chase Sun Pharmaceutical Company Information
  75. 8.13.2 Chase Sun Pharmaceutical Business Overview
  76. 8.13.3 Chase Sun Pharmaceutical Antiviral Traditional Chinese Medicine Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Chase Sun Pharmaceutical Antiviral Traditional Chinese Medicine Product Portfolio
  78. 8.13.5 Chase Sun Pharmaceutical Recent Developments
  79. 8.14 TASLY
  80. 8.14.1 TASLY Company Information
  81. 8.14.2 TASLY Business Overview
  82. 8.14.3 TASLY Antiviral Traditional Chinese Medicine Revenue and Gross Margin (2021-2026)
  83. 8.14.4 TASLY Antiviral Traditional Chinese Medicine Product Portfolio
  84. 8.14.5 TASLY Recent Developments
  85. 8.15 Yusheng Pharmaceutical
  86. 8.15.1 Yusheng Pharmaceutical Company Information
  87. 8.15.2 Yusheng Pharmaceutical Business Overview
  88. 8.15.3 Yusheng Pharmaceutical Antiviral Traditional Chinese Medicine Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Yusheng Pharmaceutical Antiviral Traditional Chinese Medicine Product Portfolio
  90. 8.15.5 Yusheng Pharmaceutical Recent Developments
  91. 8.16 Tongrentang
  92. 8.16.1 Tongrentang Company Information
  93. 8.16.2 Tongrentang Business Overview
  94. 8.16.3 Tongrentang Antiviral Traditional Chinese Medicine Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Tongrentang Antiviral Traditional Chinese Medicine Product Portfolio
  96. 8.16.5 Tongrentang Recent Developments
  97. 8.17 Wuzhou Pharmaceutical
  98. 8.17.1 Wuzhou Pharmaceutical Company Information
  99. 8.17.2 Wuzhou Pharmaceutical Business Overview
  100. 8.17.3 Wuzhou Pharmaceutical Antiviral Traditional Chinese Medicine Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Wuzhou Pharmaceutical Antiviral Traditional Chinese Medicine Product Portfolio
  102. 8.17.5 Wuzhou Pharmaceutical Recent Developments
  103. 8.18 Yiling Pharmaceutical
  104. 8.18.1 Yiling Pharmaceutical Company Information
  105. 8.18.2 Yiling Pharmaceutical Business Overview
  106. 8.18.3 Yiling Pharmaceutical Antiviral Traditional Chinese Medicine Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Yiling Pharmaceutical Antiviral Traditional Chinese Medicine Product Portfolio
  108. 8.18.5 Yiling Pharmaceutical Recent Developments
  109. 8.19 Yunnan Baiyao
  110. 8.19.1 Yunnan Baiyao Company Information
  111. 8.19.2 Yunnan Baiyao Business Overview
  112. 8.19.3 Yunnan Baiyao Antiviral Traditional Chinese Medicine Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Yunnan Baiyao Antiviral Traditional Chinese Medicine Product Portfolio
  114. 8.19.5 Yunnan Baiyao Recent Developments
  115. 8.20 Changbaishan Pharmaceutical
  116. 8.20.1 Changbaishan Pharmaceutical Company Information
  117. 8.20.2 Changbaishan Pharmaceutical Business Overview
  118. 8.20.3 Changbaishan Pharmaceutical Antiviral Traditional Chinese Medicine Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Changbaishan Pharmaceutical Antiviral Traditional Chinese Medicine Product Portfolio
  120. 8.20.5 Changbaishan Pharmaceutical Recent Developments
  121. 8.21 Zhejiang Conba Pharmaceutical
  122. 8.21.1 Zhejiang Conba Pharmaceutical Company Information
  123. 8.21.2 Zhejiang Conba Pharmaceutical Business Overview
  124. 8.21.3 Zhejiang Conba Pharmaceutical Antiviral Traditional Chinese Medicine Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Zhejiang Conba Pharmaceutical Antiviral Traditional Chinese Medicine Product Portfolio
  126. 8.21.5 Zhejiang Conba Pharmaceutical Recent Developments
  127. 8.22 Zhejiang Kanglaite Pharmaceutical
  128. 8.22.1 Zhejiang Kanglaite Pharmaceutical Company Information
  129. 8.22.2 Zhejiang Kanglaite Pharmaceutical Business Overview
  130. 8.22.3 Zhejiang Kanglaite Pharmaceutical Antiviral Traditional Chinese Medicine Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Zhejiang Kanglaite Pharmaceutical Antiviral Traditional Chinese Medicine Product Portfolio
  132. 8.22.5 Zhejiang Kanglaite Pharmaceutical Recent Developments
  133. 8.23 ZBD Pharmaceutical
  134. 8.23.1 ZBD Pharmaceutical Company Information
  135. 8.23.2 ZBD Pharmaceutical Business Overview
  136. 8.23.3 ZBD Pharmaceutical Antiviral Traditional Chinese Medicine Revenue and Gross Margin (2021-2026)
  137. 8.23.4 ZBD Pharmaceutical Antiviral Traditional Chinese Medicine Product Portfolio
  138. 8.23.5 ZBD Pharmaceutical Recent Developments
  139. 8.24 China TCM
  140. 8.24.1 China TCM Company Information
  141. 8.24.2 China TCM Business Overview
  142. 8.24.3 China TCM Antiviral Traditional Chinese Medicine Revenue and Gross Margin (2021-2026)
  143. 8.24.4 China TCM Antiviral Traditional Chinese Medicine Product Portfolio
  144. 8.24.5 China TCM Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst